Search clinical trials for: Canagliflozin (JNJ-28431754)

Total 980 results

Khoo Teck Puat Hospital

Completed

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

Type II Diabetes in Subjects BMI 27 to 32

Singapore
Shengjing Hospital

Completed

CANA/Met in Non-diabetic Women With PCOS

Polycystic Ovary Syndrome

China
University of Maryland, Baltimore
Novartis

Withdrawn

Pasireotide Treatment for Neuroendocrine Tumor

Gastro-enteropancreatic Neuroendocrine Tumor
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion

Type 1 Diabetes

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

Diabetic Nephropathy

Japan
Royal Devon and Exeter NHS Foundation Trust
King's College London; Newcastle University; NHS Tayside; University of Dundee; University... and other collaborators

Completed

TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes. (TriMaster)

Type 2 Diabetes

United Kingdom
Merck Sharp & Dohme LLC

Completed

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)

Chronic Hepatitis C
Hospital Universitari Vall d'Hebron Research Institute

Unknown

Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB) (CANA-PHH-RYGB)

Postprandial Hypoglycemia

Spain
The Cleveland Clinic
Janssen Scientific Affairs, LLC

Terminated

CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

Obesity | Diabetes Mellitus, Type 2

United States
University of Turin, Italy

Unknown

Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors (GliRACo1)

Diabetes Mellitus, Type 2 | Body Weight Changes | Arterial Hypertension

Italy
Berner Klinik Montana

Completed

Performance Under SGLT-2-Inhibitors in Humans (PUSH)

Diabetes Mellitus, Type 2

Switzerland
Johnson & Johnson Private Limited

Completed

A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting

Diabetes Mellitus, Type 2

India
Eli Lilly and Company

Completed

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus (AWARD-10)

Type 2 Diabetes Mellitus

Czechia, Hungary, United States, Mexico, Germany, Austria, Israel, Puerto Rico, Spain
Petra Pharma

Unknown

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Breast Cancer | Head and Neck Cancer | Lung Cancer | Endometrial Cancer | Colo-rectal Cancer
University of Leicester
University Hospital Birmingham

Completed

Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan (Can Do)

Diabetes Mellitus, Type 2

United Kingdom
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN 8)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, United Kingdom, Canada, Sweden, Ireland, Argentina, Brazil, Lebanon, Malaysia, Mexico, Italy
The University of Texas Health Science Center at...
Janssen Scientific Affairs, LLC

Completed

Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

United States
Virginia Commonwealth University
Janssen Scientific Affairs, LLC

Completed

Treatment of Diabetes in Patients With Systolic Heart Failure

Diabetes Mellitus, Type 2 | Heart Failure, Systolic

United States
Zhongshan Hospital Xiamen University

Unknown

Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes

Diabetic Nephropathy | Type 2 Diabetes

China
Peking Union Medical College Hospital

Unknown

Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Brigham and Women's Hospital

Unknown

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

Diabetes Mellitus, Type 2

United States
Université de Sherbrooke
Janssen Inc.

Withdrawn

Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF) (Canacardia)

Heart Failure | Type2 Diabetes
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Raymond T. Chung, MD
Merck Sharp & Dohme LLC

Withdrawn

Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant

Hepatitis C | Cardiac Transplant Disorder

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

Type 2 Diabetes Mellitus

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

Type 2 Diabetes Mellitus

Japan
Janssen Research & Development, LLC

Completed

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Cardiovascular Diseases | Diabetes Mellitus, Type 2

United States
Beth Israel Deaconess Medical Center
Janssen Scientific Affairs, LLC

Completed

Mechanisms of Weight Loss With SGLT2 Inhibition

Obesity | Overweight | Type 2 Diabetes

United States
Hvidovre University Hospital

Unknown

Glucose Absorption and Gut Hormone Secretion After Gastric Bypass

Overweight

Denmark
Janssen Research & Development, LLC

Completed

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC

Completed

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
Janssen Inc.

Completed

An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada (CanCARE)

Diabetes Mellitus, Type 2

Canada
The University of Texas Health Science Center at...
Janssen Scientific Affairs, LLC

Withdrawn

Effects of Canagliflozin on Intravascular Volume and Hemodynamics

Cardiovascular Diseases | Type2 Diabetes Mellitus

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Joslin Diabetes Center

Withdrawn

The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin (I-Can)

Diabetes, Obesity

United States
Janssen Research & Development, LLC

Completed

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

Diabetes Mellitus, Type 2

United States, Colombia, Mexico, Poland, Spain, India, Malaysia, Romania, South Africa, Sweden, Korea, Republic of, Estonia, Puerto Rico, Austria, Lithuania, Philippines, Guatemala, Iceland
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Janssen-Cilag International NV

Completed

An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan (CRATOS)

Diabetes Mellitus, Type 2

United Arab Emirates, Lebanon, Kuwait
Janssen Research & Development, LLC

Completed

Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

Obesity

United States
Lawson Health Research Institute
Janssen Inc.

Completed

Use of Canagliflozin in Conjunction With Insulin in a Real-world Setting

Type 2 Diabetes Mellitus

Canada
Janssen Research & Development, LLC

Completed

A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

Diabetes Mellitus, Type 1

United States, Canada
Pfizer

Terminated

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

Type 2 Diabetes Mellitus

United States
University of Campania "Luigi Vanvitelli"

Unknown

Glycemic Durability After Metformin Failure (AMAZING)

Type 2 Diabetes

Italy
Janssen Research & Development, LLC

Completed

The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

Diabetes Mellitus, Type 2

United States, Canada, France, Poland, Germany, Israel, India, Ukraine, Korea, Republic of, Malaysia, Netherlands, New Zealand, Singapore, Brazil, Austria, Denmark, Belgium

3

Subscribe